Amgen Research (Munich) GmbH

Quick facts

Phase 2 pipeline

• Adecatumumab and FOLFOX · Oncology
  Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.
• AMG 223 · Cardiovascular
  AMG 223 is a human monoclonal antibody that targets PCSK9.

Phase 1 pipeline

• MT110

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Amgen Research (Munich) GmbH portfolio CI brief
• Amgen Research (Munich) GmbH pipeline updates RSS

Related

• Sector hub: All tracked pharma companies